

Key Trends for Active Employees and Early Retirees Based on Paid Claims Through April 2024 Rolling Year

June 2024

83 15.0 cm MI 0.9 P2-4AC Gen Tls 1.1 [2d] G78/71 d FA4/P90 HAR/FSIO [C] G50/0.80 kHz FA5/F1/8

Change Healthcare data breach overview

Change Healthcare is a company that provides technology and managed care services to the healthcare industry



- On February 21, 2024, Change Healthcare had a cybersecurity event
- Disconnected its systems to prevent further impact
- As a result, some providers were prevented from processing and submitting prescription drug and medical claims to insurance companies



- This included payments to Aetna and Highmark
- GHIP claims were suppressed starting in late February and continuing well into April
- Results in a misrepresentation of how claims are running vs. budget and prior year



 It is our expectation that the backlog created will be cleared out by the end of FY24


Executive Summary

- Overall Allowed PMPY trend rose 3.6% from \$9,050 to \$9,377
- Inpatient medical PMPY decreased 7.6%, driven by a decrease of 9.2% in facility charges
 - Surgical admissions decreased by 15.3%; and accounted for 17% of admissions
 - Allowed amounts PMPY for maternity admissions decreased 14.2% alongside a decrease to maternity admits of 10.7%, which led to a decrease in maternity spend of 14.1%
 - Average length of stay for admissions decreased overall by 7.0%
- Outpatient medical PMPY increased by 2.9% from \$4,980 to \$5,126
 - Utilization saw the largest increases for substance abuse (26.7%), mental health (7.6%), and durable medical equipment (5.7%)
 - Allowed amount per service increased for substance abuse (30.0%); specialty drugs (medical) (16.7%); and mental health (14.8%)
 - On the medical pharmacy side, the three most costly medications were to treat cancer (Keytruda), multiple sclerosis (Ocrevus), and treatment neutropenia (low white blood cells) in cancer patients (Neulasta)
- Pharmacy payments were driving 29.1% of the cost overall and increased by 14.3% PMPY from the previous rolling year
 - Specialty drugs incurring the largest costs on the pharmacy plan were medications used to treat rheumatoid and psoriatic arthritis and other skin conditions; they were Humira, Stelara, and Tremfya

Overall Trend


Annual Trend

| | i | | |
|---------------------------------------|---------------|---------------|--------|
| | May 2022 - | May 2023 – | % |
| | Apr 2023 | Apr 2024 | Change |
| Allowed Amount | \$904,053,409 | \$951,370,974 | 5.2% |
| Coordination of Benefits ¹ | \$15,212,531 | \$27,494,338 | 80.7% |
| Out of Pocket | \$45,199,764 | \$48,524,071 | 7.4% |
| Net Payment | \$843,641,113 | \$875,352,565 | 3.8% |
| Members Avg Med or Rx | \$99,901 | \$101,458 | 1.6% |
| Allow Amt PMPY | \$9,050 | \$9,377 | 3.6% |
| Allow Amt PEPY | \$19,925 | \$20,506 | 2.9% |
| Net Pay PMPY | \$8,445 | \$8,628 | 2.2% |
| Net Pay PEPY | \$18,594 | \$18,867 | 1.5% |



¹Increase in Coordination of Benefits is largely due to the addition of PrudentRx Claims. Coordination of Benefits for PrudentRx consists of a "residual copay required by the manufacturer or the remaining drug cost after the program benefits are exhausted or unavailable. This amount is billed back to the plan" (CVS Report Definitions, State of DE State Employee Benefits Comm Savings Report). This does not include any savings, which are not included in this report and not included in the overall Allowed Amount.

Overall PMPY Trend




| | May 2022 - Apr 2023 | May 2023 - Apr 2024 | % Change |
|-------------------|---------------------|---------------------|----------|
| IP Medical | \$1,947 | \$1,799 | -7.6% |
| OP Medical | \$4,980 | \$5,126 | 2.9% |
| Prescription Drug | \$2,059 | \$2,383 | 15.7% |

Overall Eligibility Trend

Annual Eligibility Trend


| | May 2022 – | May 2023 – | |
|---------------------|------------|------------|----------|
| | Apr 2023 | Apr 2024 | % Change |
| Members Avg | 99,874 | 101,426 | 1.6% |
| Employees | 45,373 | 46,396 | 2.3% |
| Spouses | 15,483 | 15,374 | -0.7% |
| Children/Dependents | 39,018 | 39,656 | 1.6% |
| Family Size Avg | 2.2 | 2.2 | -0.7% |
| Member Age Avg | 34.4 | 34.3 | -0.1% |
| Employees | 47.0 | 46.9 | -0.2% |
| Spouses | 49.9 | 49.9 | 0.1% |
| Children/Dependents | 13.5 | 13.5 | 0.4% |




Overall Trend by Type of Service

| | Allowed | Amt PMPY Med and | Rx | Net Pay P | MPY Med and Rx | |
|---------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | May 2022 – Apr 2023 | May 2023 – Apr 2024 | % Change | May 2022 – Apr 2023 | May 2023 – Apr 2024 | % Change |
| IP Facility | \$1,690 | \$1,534 | -9.2% | \$1,613 | \$1,461 | -9.4% |
| IP Professional | \$180 | \$179 | -0.4% | \$173 | \$171 | -1.1% |
| OP Major Procedures | \$1,302 | \$1,344 | 3.2% | \$1,240 | \$1,273 | 2.7% |
| OP Radiology | \$418 | \$432 | 3.2% | \$393 | \$405 | 3.0% |
| OP Office Visits | \$613 | \$638 | 4.1% | \$524 | \$546 | 4.2% |
| OP Lab | \$317 | \$236 | -25.5% | \$286 | \$206 | -27.8% |
| OP Emergency Room | \$610 | \$630 | 3.3% | \$555 | \$571 | 3.0% |
| OP Other | \$411 | \$406 | -1.0% | \$408 | \$421 | 3.3% |
| MHSA | \$361 | \$411 | 13.9% | \$333 | \$379 | 14.0% |
| Prescription Drugs | \$2,059 | \$2,383 | 15.7% | \$1,944 | \$2,112 | 8.6% |


Allowed Amount PMPM Quarterly Trend






Cost and Use by Type of Service


| | Patients as a % of | Costs as a % of |
|--------------------------|--------------------|----------------------|
| | Total Members | Total Allowed Amount |
| IP Facility | 3.7% | 18.7% |
| IP Professional | 5.1% | 2.2% |
| OP Major Procedures | 16.1% | 16.4% |
| OP Radiology | 36.6% | 5.3% |
| OP Office Visits | 83.0% | 7.8% |
| OP Lab | 60.7% | 2.9% |
| OP Emergency Room | 15.5% | 7.7% |
| OP Other | 75.1% | 5.0% |
| MHSA | 22.1% | 5.0% |
| Prescription Drugs | 75.9% | 29.1% |
| | | |



Acute Inpatient Admission Detail


| May 2022 – Apr 2023 | May 2023 – | |
|------------------------|--|---|
| , .p. 2020 | Apr 2024 | % Change |
| 17.6 | 17.6 | -0.1% |
| 22.2 | 18.9 | -14.8% |
| 10.7 | 9.0 | -16.1% |
| 5.9 | 6.0 | 1.5% |
| 56.5 | 51.5 | -8.8% |
| \$584 | \$616 | 5.5% |
| \$447 | \$373 | -16.6% |
| \$784 | \$683 | -12.9% |
| \$78 | \$83 | 6.0% |
| \$1,894 | \$1,755 | -7.3% |
| \$566 | \$598 | 5.8% |
| \$425 | \$354 | -16.6% |
| \$752 | \$658 | -12.5% |
| \$75 | \$79 | 6.4% |
| \$1,818 | \$1,690 | -7.0% |
| | 22.2 10.7 5.9 56.5 \$584 \$447 \$784 \$784 \$78 \$1,894 \$566 \$425 \$752 \$752 \$75 | 22.218.910.79.05.96.056.551.5\$584\$616\$447\$373\$784\$683\$784\$683\$78\$83\$1,894\$1,755\$566\$598\$425\$354\$752\$658\$75\$79 |






Admission PMPY Allowed Amount Trend*

| | May 2022 – May 2023 – Apr 2023 Apr 2024 | | % Change |
|------------------|--|---------|----------|
| Allowed Amt PMPY | | | |
| Facility | \$1,673 | \$1,521 | -9.1% |
| Professional | \$171 | \$171 | -0.2% |
| Total | \$1,844 | \$1,691 | -8.3% |
| Net Pay PMPY | | | |
| Facility | \$1,599 | \$1,450 | -9.3% |
| Professional | \$164 | \$162 | -0.9% |
| Total | \$1,763 | \$1,613 | -8.5% |




Acute Admission Detail*

| | May 2022 - | May 2023 – | |
|-------------------|------------|------------|----------|
| | Apr 2023 | Apr 2024 | % Change |
| Length of Stay | | | |
| Medical | 5.7 | 5.7 | 0.5% |
| Surgical | 7.2 | 6.4 | -10.3% |
| Maternity | 3.1 | 3.0 | -3.4% |
| MHSA | 10.1 | 9.9 | -1.5% |
| Total | 5.4 | 5.3 | -1.5% |
| Allowed Amt/Admit | | | |
| Medical | \$33,234 | \$35,108 | 5.6% |
| Surgical | \$73,034 | \$75,805 | 3.8% |
| Maternity | \$20,119 | \$19,709 | -2.0% |
| MHSA | \$13,142 | \$13,734 | 4.5% |
| Total | \$33,529 | \$34,067 | 1.6% |
| Allowed Amt/Day | | | |
| Medical | \$5,869 | \$6,171 | 5.1% |
| Surgical | \$10,164 | \$11,765 | 15.8% |
| Maternity | \$6,396 | \$6,486 | 1.4% |
| MHSA | \$1,302 | \$1,382 | 6.1% |
| Total | \$6,178 | \$6,375 | 3.2% |



Acute Inpatient Admission Detail: Current Year Surgical Admits*




| Volume | |
|------------------------------|-------|
| Top 10 Principal Procedures: | 1,041 |
| Total Principal Procedures: | 5,227 |

Top 10 as a % of Total:

Cost

| Top 10 Principal Procedures (Admission Costs): | \$26.7 m |
|--|-----------|
| Total Principal Procedures (Admission Costs): | \$178.0 m |
| Top 10 as a % of Total Admission Costs: | 15.0% |

19.9%



13

Outpatient Medical Detail

| | Allowe | d Amt PMPY Med | | Pat | ients | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | May 2022 – Apr 2023 | May 2023 – Apr 2024 | % Change | May 2022 – Apr 2023 | May 2023 – Apr 2024 | % Change |
| Major Procedures | \$1,302 | \$1,344 | 3.2% | 16,934 | 18,218 | 7.6% |
| Specialty Drugs (Medical) | \$575 | \$671 | 16.7% | 3,459 | 3,654 | 5.6% |
| Professional Office Visits | \$613 | \$638 | 4.1% | 93,558 | 93,878 | 0.3% |
| Emergency Rooms | \$610 | \$630 | 3.3% | 17,289 | 17,550 | 1.5% |
| Radiology | \$418 | \$432 | 3.2% | 41,100 | 41,373 | 0.7% |
| Other Outpatient Services | \$411 | \$406 | -1.0% | 81,159 | 84,949 | 4.7% |
| Laboratory | \$317 | \$236 | -25.5% | 72,162 | 68,681 | -4.8% |
| Mental Health | \$256 | \$294 | 14.8% | 23,004 | 24,267 | 5.5% |
| Substance Abuse | \$24 | \$31 | 30.0% | 953 | 1,062 | 11.4% |
| PT, OT, Speech Therapy | \$139 | \$150 | 8.2% | 15,424 | 15,694 | 1.8% |
| Injections and Medications | \$85 | \$74 | -12.7% | 12,412 | 12,375 | -0.3% |
| Supplies and Devices | \$90 | \$92 | 1.9% | 13,904 | 14,565 | 4.8% |
| Dialysis | \$65 | \$58 | -11.0% | 97 | 92 | -5.2% |
| Durable Medical Equipment | \$36 | \$35 | -4.4% | 4,562 | 4,608 | 1.0% |

Outpatient Medical Detail

| | Utilizatio | n (Services per 100 | 0) | Price (Allowed A | mount per Service) | |
|----------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|
| | May 2022 – Apr 2023 | May 2023 – Apr 2024 | % Change | May 2022 – Apr 2023 | May 2023 – Apr 2024 | % Change |
| Major Procedures | 1,916.9 | 1,889.8 | -1.4% | \$679 | \$711 | 4.7% |
| Specialty Drugs (Medical) | 283.9 | 290.2 | 2.2% | \$2,025 | \$2,311 | 14.1% |
| Professional Office Visits | 5,670.2 | 5,537.1 | -2.3% | \$108 | \$115 | 6.6% |
| Emergency Rooms | 2,097.2 | 2,020.5 | -3.7% | \$291 | \$312 | 7.2% |
| Radiology | 1,760.1 | 1,692.6 | -3.8% | \$238 | \$255 | 7.3% |
| Other Outpatient Services | 3,478.4 | 3,580.0 | 2.9% | \$118 | \$114 | -3.8% |
| Laboratory | 7,665.4 | 7,060.2 | -7.9% | \$41 | \$33 | -19.2% |
| Mental Health | 2,537.7 | 2,731.1 | 7.6% | \$101 | \$108 | 6.7% |
| Substance Abuse | 179.1 | 227.0 | 26.7% | \$133 | \$136 | 2.6% |
| PT, OT, Speech Therapy | 4,237.6 | 4,190.4 | -1.1% | \$33 | \$36 | 9.4% |
| Injections and Medications | 800.2 | 776.6 | -2.9% | \$106 | \$96 | -10.0% |
| Supplies and Devices | 1,120.9 | 1,149.5 | 2.5% | \$81 | \$80 | -0.6% |
| Dialysis | 102.1 | 97.0 | -5.0% | \$636 | \$596 | -6.3% |
| Durable Medical Equipment | 194.9 | 206.0 | 5.7% | \$185 | \$168 | -9.6% |

Outpatient Medical Detail: Professional Office Visits


| | | | | | | | | | la <i>e</i> e e - | | | |
|--|---------------------------|------------------------------|---------------------------|-------------------------|---|-----------------|-------------|---------------------|-------------------|------------|----------------|----------|
| | | % Visits | | | Allowed Amt | | | ved Amount/ | | | Visits per 100 | 00 |
| | • | May 2023 - | Change | May 2022 - | May 2023 - | Change | - | - May 2023 - | % Changa | May 2022 - | May 2023 - | % Change |
| | Apr 2023 36.3% | Apr 2024 % 36.0% | • | Apr 2023 35.6% | - | Change -0.5% | Apr 2023 | Apr 2024 | | Apr 2023 | Apr 2024 | % Change |
| Specialist Visits Non-Specialist Visits | 63.79 | | | | | | | | | , | - | |
| Total | 100.09 | | | 100.0% | | | §12 \$12 | | | | | |
| Iotai | 100.07 | |) | 100.076 | 100.076 |) | <u>, 12</u> | <u>, 51</u> | 0.070 | · · · · · | s per Allowe | |
| | | | | | | | | | | | - | Visit |
| | | | | | | | Der | rmatology | | | 197 | \$98 |
| | | Top | 5 Specialis | to | | | | hopaedic Sur | gerv | | 189 | \$129 |
| 250 | | ТОр | o opecialis | 15 | | \$180 | | diovascular D | | logy | 110 | \$132 |
| $\wedge \qquad \wedge \qquad \frown \qquad $ | | | | | | \$160 \$140 | | diatry | , | 0/ | 112 | \$93 |
| 200 | \sim / | | | | \sim | \$140 | E Em | , ergency Med | icine | | 68 | \$165 |
| 120 | | | | - | | \$100 | 2 | ropractor/DC | | | 60 | \$84 |
| 100 — AXI | | • | | | | \$80 | Op | hthalmology | | | 55 | \$118 |
| 50 | | | | . | | \$40 | D | ology | | | 50 | \$122 |
| 0 | | | | | | \$20 \$0 | Oto | olaryngology | | | 53 | \$158 |
| Dermatology Orthopaedic Surgery Cardiovascular Dis Cardiov | podiatry podiatry Medicin | practor/DCM Ophthalmology | Urology angology | Medicine (NEC) Neurolos | Metabolism Allerei & Immunology Onc | 01051 | Pai | n Mgmt/Pain | Medicine | e | 52 | \$116 |
| Derman Desedic St. DislCart. | PC Nee Nee | practor/DCM ophthalmology | Urology Otolan/ngology | Neticine (NEC) Neurolog | Metab One | | Sur | geon (NEC) | | | 37 | \$141 |
| Orthonascular | EWers Chr. | | Pain Mgmm | doctinolos | AllerB | | Ne | urology | | | 37 | \$167 |
| C _{8to} . | | | X. | Ene | | | Enc | docrinology & | Metabol | ism | 39 | \$141 |
| | | Visits per 1000 | -Allowed | Amout Per Visit | | | Alle | ergy & Immur | nology | | 41 | \$156 |
| | | | | | | | On | cology | | | 40 | \$155 |
| | | | | | | | Тор | o 15 | | | 1,136 | \$125 |
| | | | | | | | All | Other Specia | lists | | 333 | \$156 |

Total All Specialists

1,465


Outpatient Medical Detail: Radiology

| | Services per 1000 | | | Allowed | l Amount per S | Service | Allowed Amount PMPY | | | Net Pay PMPY | | |
|------------------|-------------------|------------|----------|------------|----------------|----------|---------------------|------------|----------|--------------|------------|----------|
| Outpatient | | | | | | | | | | | | |
| Radiology | May 2022 - | May 2023 - | | May 2022 - | May 2023 - | | May 2022 - | May 2023 - | | May 2022 - | May 2023 - | |
| Services | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change |
| CAT Scans | 92.9 | 90.8 | -2.3% | \$425 | \$445 | 4.9% | \$39 | \$40 | 2.5% | \$36 | \$36 | -0.4% |
| MRIs | 117.9 | 119.4 | 1.3% | \$553 | \$566 | 2.3% | \$65 | \$68 | 3.6% | \$60 | \$63 | 4.0% |
| Mammograms | 431.3 | 423.6 | -1.8% | \$120 | \$124 | 3.0% | \$52 | \$52 | 1.2% | \$51 | \$51 | 1.3% |
| PET Scans | 6.1 | 7.5 | 23.6% | \$2,873 | \$2,710 | -5.7% | \$17 | \$20 | 16.6% | \$17 | \$20 | 16.2% |
| Nuclear Medicine | 30.3 | 28.7 | -5.1% | \$738 | \$898 | 21.7% | \$22 | \$26 | 15.4% | \$22 | \$24 | 12.7% |
| Therapeutic | 104.7 | 98.0 | -6.4% | \$1,041 | \$1,145 | 10.0% | \$109 | \$112 | 2.9% | \$107 | \$111 | 3.2% |
| Ultrasounds | 426.0 | 393.2 | -7.7% | \$168 | \$179 | 6.4% | \$72 | \$70 | -1.8% | \$65 | \$64 | -1.6% |
| X-Rays | 518.7 | 499.0 | -3.8% | \$74 | \$78 | 5.7% | \$38 | \$39 | 1.7% | \$32 | \$33 | 1.9% |
| Other | 32.3 | 32.4 | 0.3% | \$105 | \$119 | 12.9% | \$3 | \$4 | 13.3% | \$3 | \$4 | 12.6% |
| Total | 1760.1 | 1692.6 | -3.8% | \$238 | \$255 | 7.3% | \$418 | \$432 | 3.2% | \$393 | \$405 | 3.0% |



Outpatient Medical Detail: Laboratory

| | Se | rvices per 100 | 0 | Allowed | Amount per | Service | Allowed Amount PMPY | | | Net Pay PMPY | | |
|------------------------|------------|----------------|----------|------------|------------|----------|---------------------|------------|----------|--------------|------------|----------|
| Outpatient Lab | May 2022 - | May 2023 - | | May 2022 - | May 2023 - | | May 2022 - | May 2023 - | | May 2022 - | May 2023 - | |
| Services | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change |
| Chemistry Tests | 3689.3 | 3860.5 | 4.6% | \$21 | \$21 | 1.2% | \$76 | \$80 | 5.9% | \$60 | \$64 | 5.3% |
| Hematology | 575.3 | 582.2 | 1.2% | \$17 | \$14 | -18.7% | \$10 | \$8 | -17.7% | \$7 | \$7 | 8.4% |
| Immunology | 825.7 | 536.8 | -35.0% | \$30 | \$27 | -8.6% | \$25 | \$15 | -40.6% | \$24 | \$13 | -44.4% |
| Microbiology | 1593.7 | 1144.4 | -28.2% | \$72 | \$42 | -41.3% | \$115 | \$48 | -57.8% | \$110 | \$43 | -60.5% |
| Pathology | 461.2 | 431.2 | -6.5% | \$140 | \$135 | -3.9% | \$65 | \$58 | -10.1% | \$60 | \$54 | -9.7% |
| Urinalysis | 316.5 | 317.2 | 0.2% | \$5 | \$5 | 1.7% | \$2 | \$2 | 1.9% | \$1 | \$1 | 3.0% |
| Other | 203.8 | 187.9 | -7.8% | \$127 | \$133 | 4.4% | \$26 | \$25 | -3.7% | \$24 | \$24 | -1.4% |
| Total | 7665.4 | 7060.2 | -7.9% | \$41 | \$33 | -19.2% | \$317 | \$236 | -25.5% | \$286 | \$206 | -27.8% |



Prescription Drug Detail*

Annual Trend

| | | May 2022 - | May 2023 - | |
|------------|-------------------------------|------------|------------------|----------|
| | | Apr 2023 | Apr 2024 | % Change |
| Total | Allowed Amount PMPY | \$2,059 | \$2 <i>,</i> 383 | 15.7% |
| Ĕ | Net Pay PMPY | \$1,944 | \$2,112 | 8.6% |
| | Out of Pocket PMPY | \$108 | \$119 | 10.5% |
| | Patients per 1000 | 806.2 | 758.7 | -5.9% |
| | Allowed Amount per Day Supply | \$4.42 | \$5.05 | 14.1% |
| | Days Supply PMPY | 465.6 | 472.1 | 1.4% |
| der | Allowed Amount PMPY | \$104 | \$155 | 48.8% |
| Mail Order | Net Pay PMPY | \$98 | \$145 | 48.8% |
| lail | Out of Pocket PMPY | \$6 | \$8 | 29.0% |
| Σ | Patients per 1000 | 44.8 | 47.7 | 6.5% |
| | Allowed Amount per Day Supply | \$2.59 | \$4.00 | 54.4% |
| | Days Supply PMPY | 40.1 | 38.7 | -3.6% |
| Retail | Allowed Amount PMPY | \$975 | \$1,094 | 12.1% |
| Re | Net Pay PMPY | \$876 | \$984 | 12.3% |
| | Out of Pocket PMPY | \$94 | \$103 | 10.1% |
| | Patients per 1000 | 802.9 | 753.6 | -6.1% |
| | Allowed Amount per Day Supply | \$2.34 | \$2.58 | 10.3% |
| | Days Supply PMPY | 417.5 | 424.6 | 1.7% |
| alty | Allowed Amount PMPY | \$980 | \$1,134 | 15.8% |
| Specialty | Net Pay PMPY | \$970 | \$983 | 1.3% |
| Spe | Out of Pocket PMPY | \$8 | \$8 | 0.7% |
| | Patients per 1000 | 39.1 | 40.4 | 3.4% |
| | Allowed Amount per Day Supply | \$122.80 | \$128.78 | 4.9% |
| ative | Days Supply PMPY | 8.0 | 8.8 | 10.4% |




*Specialty drugs on this slide includes drugs covered under the prescription drug benefit and excludes drugs covered under the medical plans.

© 2024 Merative

Prescription Drug Detail: Non-Specialty Drugs

Annual Trend

| | Allowed Amount PMPY | | Net Pay PMPY | | Allowed Amt per Days Supply | | Days Supply PMPY | | | Generic Efficiency | | ncy | | | |
|----------------------------|---------------------|----------|--------------|--------------|-----------------------------|----------|------------------|------------|----------|--------------------|------------|----------|--------------|----------|----------|
| | May 2022 | May 2023 | | May 2022 | May 2023 | | May 2022 | May 2023 | | May 2022 | May 2023 | | May 2022 | May 2023 | |
| Therapeutic Class | - Apr 2023 - | Apr 2024 | % Change | - Apr 2023 - | Apr 2024 | % Change | - Apr 2023 | - Apr 2024 | % Change | - Apr 2023 | - Apr 2024 | % Change | - Apr 2023 - | Apr 2024 | % Change |
| Hormones & Synthetic Subst | \$482 | \$634 | 31.6% | \$456 | \$605 | 32.7% | \$6 | \$7 | 25.9% | 81 | 85 | 4.5% | 93.4% | 94.1% | 0.7% |
| Central Nervous System | \$244 | \$229 | -6.0% | \$215 | \$200 | -7.1% | \$2 | \$2 | -8.8% | 114 | 117 | 3.1% | 96.2% | 97.9% | 1.8% |
| Cardiovascular Agents | \$49 | \$57 | 17.4% | \$36 | \$44 | 22.5% | \$0 | \$0 | 16.2% | 119 | 121 | 1.1% | 99.9% | 99.9% | 0.0% |
| Blood Form/Coagul Agents | \$48 | \$51 | 6.1% | \$45 | \$48 | 5.7% | \$9 | \$9 | 2.6% | 6 | 6 | 3.4% | 100.0% | 99.7% | -0.3% |
| Gastrointestinal Drugs | \$39 | \$40 | 2.5% | \$34 | \$35 | 1.3% | \$2 | \$2 | -1.5% | 25 | 26 | 4.0% | 99.9% | 99.9% | 0.0% |
| Serums, Toxoids, Vaccines | \$25 | \$37 | 48.2% | \$25 | \$37 | 48.3% | \$54 | \$108 | 100.9% | 0 | 0 | -26.2% | 100.0% | 100.0% | 0.0% |
| Autonomic Drugs | \$34 | \$30 | -11.1% | \$29 | \$25 | -14.1% | \$3 | \$2 | -12.2% | 12 | 12 | 1.2% | 99.9% | 99.9% | 0.0% |
| Anti-Infective Agents | \$23 | \$29 | 25.6% | \$17 | \$22 | 29.2% | \$2 | \$2 | 19.7% | 12 | 13 | 4.9% | 100.0% | 100.0% | 0.0% |
| Eye, Ear, Nose Throat | \$28 | \$27 | -1.6% | \$23 | \$22 | -4.6% | \$2 | \$3 | 62.4% | 14 | 9 | -39.5% | 98.3% | 97.6% | -0.8% |
| Diagnostic Agents | \$31 | \$26 | -18.3% | \$27 | \$20 | -26.3% | \$3 | \$3 | 2.1% | 10 | 8 | -20.0% | 0.0% | 0.0% | 0.0% |
| All Other Values | \$78 | \$89 | 14.0% | \$65 | \$71 | 8.6% | \$1 | \$1 | 9.1% | 64 | 67 | 4.5% | 99.3% | 99.3% | 0.0% |
| Total | \$1,080 | \$1,249 | 15.7% | \$974 | \$1,129 | 15.9% | \$2 | \$3 | 14.3% | 458 | 463 | 1.2% | 97.9% | 98.5% | 0.6% |



Specialty Drug Detail¹

| | Allowed Amount | | | Patients | | | Allowed Amount per Patient | | | |
|------------------------|------------------------|------------------------|----------|------------------------|------------------------|----------|----------------------------|------------------------|----------|--|
| | May 2022 - Apr 2023 | May 2023 – Apr 2024 | % Change | May 2022 - Apr 2023 | May 2023 - Apr 2024 | % Change | May 2022 - Apr 2023 | May 2023 - Apr 2024 | % Change | |
| Medical Specialty | \$57,417,250 | \$68,032,660 | 18.5% | 3,460 | 3,655 | 5.6% | \$16,595 | \$18,614 | 12.2% | |
| Prescription Specialty | \$97,874,003 | \$115,087,413 | 17.6% | 4,339 | 4,571 | 5.3% | \$22,557 | \$25,178 | 11.6% | |

| Тој | o 10 Specialty Drugs Through Medical Plans | Allowed Amount | Patients | Allowed/Patient |
|----------------|--|----------------|----------|-----------------|
| J9271 | Inject pembrolizumab 1 mg | \$8,069,267 | 64 | \$126,082 |
| J2350 | Inject, ocrelizumab, 1 mg | \$3,667,504 | 55 | \$66,682 |
| J2506 | Inject, pegfilgrastim, excl biosimilar, 0.5 mg | \$3,040,741 | 61 | \$49,848 |
| J9299 | Inject nivolumab 1 mg | \$2,495,787 | 21 | \$118,847 |
| J9144 | Inj, daratumumab, 10 mg and hyaluronidase-fihj | \$2,234,305 | 17 | \$131,430 |
| J3380 | Inject, vedolizumab, intravenous, 1 mg | \$2,096,839 | 54 | \$38,830 |
| 96413 | CHEMOTX ADMN IV NFS TQ UP 1 HR | \$1,758,833 | 561 | \$3,135 |
| J2323 | Injection natalizumab, 1 mg | \$1,509,058 | 15 | \$100,604 |
| J9306 | Inject, pertuzumab, 1 mg | \$1,169,223 | 15 | \$77,948 |
| J0585 | Injection onabotulinumtoxinA, 1 unit | \$1,145,893 | 316 | \$3,626 |
| Total Top 10 | | \$26,041,558 | 863 | \$30,176 |
| Percent of Ove | rall Total (Medical Specialty) | 38.3% | 23.6% | |

¹Specialty drugs are defined in a Merative service category group and include drugs paid under the prescription benefit and the medical benefit. Although there is no consensus definition, the continuum of drugs included may have the following characteristics: relatively costly (at least \$670 per month for a 30-day supply, according to CMS); often injected or infused; involve a significant degree of patient education, monitoring and management; require special preparation, handling or monitoring; and may be biologically created vs. a chemical compound.


Specialty Drug Detail

| Top 15 Through the Prescription Plan | | |
|---|----------------|----------|
| | Allowed Amount | Patients |
| HUMIRA | \$12,456,219 | 223 |
| STELARA | \$7,856,006 | 84 |
| TREMFYA | \$6,320,319 | 108 |
| DUPIXENT PEN | \$4,940,191 | 202 |
| SKYRIZI | \$4,916,329 | 88 |
| ENBREL | \$2,795,839 | 64 |
| COSENTYX | \$2,596,073 | 58 |
| TALTZ | \$2,408,274 | 42 |
| DUPIXENT PFS | \$2,179,712 | 96 |
| TRIKAFTA | \$2,148,652 | 7 |
| BIKTARVY | \$1,975,300 | 66 |
| OTEZLA | \$1,936,937 | 70 |
| VERZENIO | \$1,831,847 | 17 |
| SPRYCEL | \$1,779,056 | 14 |
| RINVOQ | \$1,686,310 | 51 |
| Total Top 15 | \$57,827,065 | 1,190 |
| Percent of Overall Total (Rx Specialty) | 50.2% | 26.0% |

Mental Health and Substance Abuse Detail

| | | Iental Health | | Sut | | |
|-----------------------------|------------|---------------|----------|------------|------------|----------|
| | May 2022 – | May 2023 – | | May 2022 – | May 2023 – | |
| | Apr 2023 | Apr 2024 | % Change | Apr 2023 | Apr 2024 | % Change |
| Overall | | | | | | |
| Patients per 1000 Inpatient | 4.2 | 4.3 | 3.0% | 1.4 | 1.5 | 1.2% |
| Pats per 1000 Outpatient | 207.1 | 214.4 | 3.5% | 8.6 | 9.4 | 9.4% |
| Inpatient | | | | | | |
| Allow Amt PMPY Adm Acute | \$52 | \$58 | 12.5% | \$26 | \$24 | -6.9% |
| Net Pay PMPY Adm Acute | \$50 | \$57 | 13.8% | \$25 | \$23 | -8.6% |
| Allow Amt Per Adm Acute | \$12,985 | \$14,987 | 15.4% | \$13,468 | \$11,425 | -15.2% |
| Days LOS Admit Acute | 10.0 | 10.2 | 1.5% | 10.2 | 9.5 | -7.1% |
| Admits Per 1000 Acute | 4.0 | 3.9 | -2.5% | 1.9 | 2.1 | 9.7% |
| Outpatient | | | | | | |
| Allow Amt PMPY OP Med | \$251 | \$289 | 15.0% | \$24 | \$31 | -49.8% |
| Net Pay PMPY OP Med | \$229 | \$263 | 14.9% | \$21 | \$28 | -49.9% |
| Allow Amt Per Svc OP Med | \$102 | \$110 | 7.7% | \$132 | \$136 | 15.5% |
| Svcs Per 1000 OP Med | 2458.8 | 2625.6 | 6.8% | 178.4 | 226.0 | -56.5% |

Preventive Visits and Screening Overview




Clinical Overview

| Annual Trend: Conditions of Interest | Allowed Amount PMPY (Medical) | | | Patie | ents per 1000 | | Allowed Amount per Patient (Medical) | | |
|--------------------------------------|-------------------------------|------------|--------|------------|---------------|--------|--------------------------------------|-------------|--------|
| | May 2022 – | May 2023 – | | May 2022 – | May 2023 – | | May 2022 – | May 2023 – | |
| | Apr 2023 | Apr 2024 | Change | Apr 2023 | Apr 2024 | Change | Apr 2023 | Apr 2024 | Change |
| Asthma | \$29.16 | \$26.73 | -8.3% | 37.4 | 36.8 | -1.8% | \$701.05 | \$652.13 | -7.0% |
| Cancer - Breast | \$95.92 | \$148.63 | 54.9% | 7.0 | 7.1 | 2.0% | \$12,317.04 | \$18,639.89 | 51.3% |
| Cancer - Colon | \$25.10 | \$31.76 | 26.5% | 1.6 | 1.6 | 0.4% | \$14,412.63 | \$18,104.55 | 25.6% |
| Cancer - Lung | \$34.03 | \$33.41 | -1.8% | 1.2 | 1.2 | -2.6% | \$25,184.36 | \$25,298.23 | 0.5% |
| Cancer - Skin | \$29.68 | \$31.75 | 7.0% | 27.9 | 28.3 | 1.5% | \$956.90 | \$1,005.24 | 5.1% |
| Cerebrovascular Disease | \$81.98 | \$84.12 | 2.6% | 11.6 | 11.7 | 1.3% | \$6,368.30 | \$6,426.80 | 0.9% |
| Chronic Obstruc Pulm Dis(COPD) | \$12.33 | \$11.40 | -7.5% | 5.3 | 5.3 | 0.0% | \$2,094.66 | \$1,930.67 | -7.8% |
| Congestive Heart Failure | \$17.80 | \$14.67 | -17.6% | 3.2 | 3.3 | 3.7% | \$5,038.08 | \$3,991.15 | -20.8% |
| Coronary Artery Disease | \$96.62 | \$103.06 | 6.7% | 14.4 | 14.3 | -1.2% | \$6,025.06 | \$6,482.71 | 7.6% |
| Diabetes | \$102.66 | \$100.81 | -1.8% | 91.6 | 100.1 | 9.2% | \$1,007.84 | \$903.35 | -10.4% |
| Hypertension, Essential | \$75.38 | \$89.79 | 19.1% | 119.2 | 115.0 | -3.5% | \$569.08 | \$700.20 | 23.0% |
| Mental Hlth - Depression | \$117.77 | \$135.16 | 14.8% | 95.8 | 98.5 | 2.9% | \$1,106.20 | \$1,229.97 | 11.2% |
| Osteoarthritis | \$194.38 | \$178.75 | -8.0% | 62.8 | 61.4 | -2.2% | \$2,783.98 | \$2,609.48 | -6.3% |
| Renal Function Failure | \$108.12 | \$92.52 | -14.4% | 10.6 | 11.2 | 5.6% | \$9,176.91 | \$7,408.54 | -19.3% |
| Spinal/Back Disord, Low Back | \$182.55 | \$169.67 | -7.1% | 97.2 | 95.1 | -2.2% | \$1,689.84 | \$1,600.10 | -5.3% |
| Pneumonia | \$25.54 | \$32.00 | 25.3% | 7.5 | 8.4 | 11.9% | \$3,048.76 | \$3,402.69 | 11.6% |
| Pregnancy | \$304.30 | \$282.81 | -7.1% | 25.0 | 24.3 | -2.5% | \$10 <i>,</i> 970.64 | \$10,418.92 | -5.0% |

Risk Profile¹ (Based on FY23 Claims Experience)

| | Member Age Avg | Allowed Amount | Allow Amt PMPY | Patients |
|------------|----------------|----------------|----------------|----------|
| Healthy | 25.1 | \$21,306,114 | \$702 | 27,410 |
| Stable | 29.8 | \$63,994,131 | \$2,624 | 25,936 |
| At Risk | 39.8 | \$162,793,182 | \$6,605 | 26,519 |
| Struggling | 46.1 | \$331,567,653 | \$19,273 | 18,487 |
| In Crisis | 50.8 | \$303,273,429 | \$88,302 | 3,896 |



© 2024 Merative

¹Definitions for each of the risk category are included on the next slide.

Risk Categories

- Healthy represents nearly 50% of the privately insured under-65 U.S. population, who account for less than 5% of total healthcare cost. Most patients in this category are infrequent or non-utilizers of the healthcare system, most often being treated for occasional low severity acute conditions.
- **Stable** represents nearly 25% of the privately insured under-65 U.S. population, who account for 10-15% of total healthcare cost. Most patients in this category are somewhat active utilizers of the healthcare system, most often being treated for low-severity acute conditions.
- At Risk represents between 15 and 20% of the privately insured under-65 U.S. population, who account for 20-25% of total healthcare cost. Most patients in this category are active utilizers of the healthcare system, most often being treated for multiple medium-severity acute conditions and/or low-severity chronic conditions.
- **Struggling** represents between 5 and 10% of the privately insured under-65 U.S. population, who account for 25-30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple high-severity acute conditions and/or medium-severity chronic conditions.
- In-Crisis represents the top 2% of the privately insured under-65 U.S. population, who account for approximately 30% of total healthcare cost. Most patients in this category are heavy utilizers of the healthcare system, most often being treated for multiple severe acute and/or chronic conditions.